Trial Profile

A phase Ia trial of SEL-212 for treatment of refractory and tophaceous gout and tumor lysis syndrome

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 14 Dec 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SEL 212 (Primary)
Indications Gout; Tumour lysis syndrome
Focus Adverse reactions; Proof of concept
Sponsors Selecta Biosciences

Most Recent Events

07 Dec 2016 Results published in the Selecta Biosciences Media Release
07 Dec 2016 According to a Selecta Biosciences media release, all patient visits has been completed in this and other Phase I trial (266205).
26 Oct 2016 Results from this and another phase I trial will be presented at the 11th Annual Immunization and Vaccine Summit (IMVACS) 2016, according to a Selecta Biosciences media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com